The company will work with USC researchers in a year-long study aimed at assessing the clinical utility of EntroGen's PCR-based liquid biopsy test for EGFR mutations.
The test is a targeted next-gen sequencing assay that uses Illumina's MiniSeq, MiSeq, and NextSeq platforms to detect somatic mutations in BRCA1 and BRCA2.
EntroGen this week announced the availability of expanded colorectal cancer screening products.
Myriad Releases Interim PROCEDE 500 Clinical Utility Trial Data for Prolaris
The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.